News|Articles|November 18, 2026

FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • Cemdisiran is a complement C5-directed siRNA that suppresses hepatic C5 production, distinguishing it mechanistically from C5-binding agents and enabling quarterly subcutaneous dosing.
  • NIMBLE met primary MG-ADL and key secondary QMG endpoints at week 24, with higher clinically meaningful response rates versus placebo and early, deepening improvements.
SHOW MORE

Cemdisiran (Livsayis), Regeneron’s complement C5-directed siRNA dosed four times a year, can now treat adults in the US who have AChR-antibody-positive generalized myasthenia gravis.

The FDA has approved cemdisiran, marketed as Livsayis, for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The complement C5-directed small interfering RNA (siRNA) therapeutic is dosed once every 3 months as a subcutaneous injection.1

Regeneron describes Livsayis as the first and only approved siRNA therapy for gMG and the only approved gMG treatment given subcutaneously four times a year. The drug degrades the messenger RNA that encodes complement component 5 (C5), lowering circulating C5 levels and limiting terminal complement activation; it treats the AChR-antibody-positive form of gMG, the predominant form of the disease, which affects an estimated 85,000 people in the US.

The approval is supported by the phase 3 NIMBLE trial, a randomized, double-blind, placebo-controlled study that enrolled adults with AChR-antibody-positive gMG across 4 treatment arms: cemdisiran alone every 3 months, cemdisiran plus the C5 inhibitor pozelimab every 4 weeks, pozelimab alone every 4 weeks, and placebo every 4 weeks, with background immunosuppressants allowed at investigator discretion.1,2

“In the Phase 3 NIMBLE trial, Livsayis delivered rapid, deep disease control," Tuan Vu, MD, professor of neurology and division director of neuromuscular medicine and electromyography laboratories at the University of South Florida Morsani College of Medicine, and a global principal investigator on the trial, said in a statement.1

On the primary endpoint, change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline to week 24, cemdisiran improved scores by a least-squares mean of 4.5 points versus 2.2 points with placebo, a placebo-adjusted difference of 2.3 points (P =.0005). A 3-point or greater improvement, considered clinically meaningful, was reached by 76.6% of cemdisiran-treated patients versus 44.1% on placebo (P <.001).1

On the key secondary endpoint, the Quantitative Myasthenia Gravis (QMG) score improved by 4.2 points with cemdisiran versus 1.5 points with placebo, a placebo-adjusted difference of 2.8 points (P =.0015), and 48.4% of cemdisiran-treated patients achieved a 5-point or greater QMG improvement, compared with 19.0% on placebo (P <.001). Regeneron reported that improvement began as early as 2 weeks after the first dose and deepened over time, with disease control maintained through the end of each 3-month dosing interval.1

During the trial's double-blind period, treatment-emergent adverse events occurred in 69.2% of cemdisiran-treated patients and 77.1% of those on placebo, and no deaths occurred.2 The most common adverse reactions, occurring in at least 5% of cemdisiran-treated patients and more often than with placebo, were injection site reactions, viral infections, and urinary tract infections.1 In the trial's open-label extension, 1 cemdisiran-treated patient with substantial comorbidities died of pneumonia while on concomitant immunosuppressive therapy.2

Livsayis carries a boxed warning for serious, life-threatening, or fatal meningococcal infections and is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program that requires meningococcal vaccination at least 2 weeks before the first dose; the drug is contraindicated in patients with an active meningococcal infection.

“Livsayis is Regeneron's first approved medicine in neurology,” George D. Yancopoulos, MD, PhD, Regeneron's board co-chair, president, and chief scientific officer, said in a statement.1 "As Regeneron's first approved siRNA therapy, this approval marks a meaningful step forward for our neuroscience pipeline.”

“Individuals living with gMG experience profound muscle weakness that can affect how they talk, see, breathe and move,” Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America, said in a statement. “This approval is a positive milestone for the gMG community.”

A fourth complement-targeted option, working further upstream

Livsayis becomes the fourth complement-targeted therapy approved for gMG, following the C5 inhibitors eculizumab and ravulizumab and the C5-binding nanobody gefurulimab, approved earlier this month.3 Unlike those 3 agents, which bind circulating C5 protein directly, cemdisiran works further upstream, using RNA interference to reduce hepatic production of C5 before it enters circulation; its quarterly dosing schedule is also less frequent than any previously approved complement inhibitor in gMG.2 In NIMBLE, adding the C5-inhibiting antibody pozelimab to cemdisiran did not improve on cemdisiran alone, supporting Regeneron's decision to pursue monotherapy.

Regeneron first reported positive NIMBLE topline data in August 2025, when cemdisiran monotherapy met the trial's primary and key secondary endpoints. The full NIMBLE results were later published in The Lancet and presented at the 2026 American Academy of Neurology Annual Meeting, and the FDA and EMA accepted regulatory applications for cemdisiran in June 2026, with the FDA granting priority review and setting a target action date in November 2026. Regeneron develops, manufactures, and commercializes Livsayis under a worldwide licensing agreement with Alnylam Pharmaceuticals, whose RNA interference platform underlies the drug's mechanism.1

REFERENCES
1. Livsayis™ (cemdisiran) approved by the FDA as first and only siRNA therapy in generalized myasthenia gravis and only treatment with four-times-a-year subcutaneous dosing. News release. Regeneron Pharmaceuticals, Inc. Published November 18, 2026. Accessed November 18, 2026. https://investor.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy
2. Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2
3. KLYGEFA™ (gefurulimab-gaks) approved in the US for the treatment of generalized myasthenia gravis (gMG) in adult patients. News release. Alexion, AstraZeneca Rare Disease. Published November 16, 2026. Accessed November 18, 2026. https://www.astrazeneca-us.com/media/press-releases/2026/KLYGEFA-gefurulimab-gaks-approved-in-the-US-for-the-treatment-of-generalized-myasthenia-gravis-gMG-in-adult-patients.html

Related to this article